Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial

This publication has 23 references indexed in Scilit:

• Efficacy and Safety of a New Prolonged Release Formulation of Alfuzosin 10 mg Once Daily versus Alfuzosin 2.5 mg Thrice Daily and Placebo in Patients with Symptomatic Benign Prostatic Hyperplasia
  European Urology, 2000
• The pharmacological perspective: role for the sympathetic nervous system in micturition and sexual function
  Prostate Cancer and Prostatic Diseases, 1999
• PROSTATE SELECTIVITY OF ALPHA 1 ADRENOCEPTOR BLOCKERS
  Journal of Urology, 1999
• A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
  European Urology, 1999
• Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice
  Prostate Cancer and Prostatic Diseases, 1998
• Sustained-Release Alfuzosin, Finasteride and the Combination of Both in the Treatment of Benign Prostatic Hyperplasia
  European Urology, 1998
• Quantification and distribution of α₁‐adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions
  British Journal of Pharmacology, 1997
• Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia)
  British Journal of Urology, 1997
• Urinary Flow Rates in Patients with Benign Prostatic Hypertrophy following Treatment with Alfuzosin
  British Journal of Urology, 1992
• Alfuzosin for treatment of benign prostatic hypertrophy
  The Lancet, 1991